ProfileGDS5678 / 1433931_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 77% 76% 76% 76% 78% 77% 77% 76% 76% 77% 76% 76% 77% 76% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.1406577
GSM967853U87-EV human glioblastoma xenograft - Control 25.1514376
GSM967854U87-EV human glioblastoma xenograft - Control 35.1369176
GSM967855U87-EV human glioblastoma xenograft - Control 45.2761976
GSM967856U87-EV human glioblastoma xenograft - Control 55.3934378
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.1503977
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.144877
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.1409576
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.1504376
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.2905977
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.0755276
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.1205676
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.1474877
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.0798676